Case Studies Overview

Case Studies


FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.


Publications


2021


Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry

Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber

DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1519

Poster Presented at: American Thoracic Society (ATS)

Conference dates: May 14, 2021 - May 19, 2021


Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)

Janna Radtchenko, Jasvinder A. Singh, MD, MPH, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD

10.18553/jmcp.2021.27.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 12, 2021 - April 16, 2021


A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A

Shawn X. Sun, Andrew Frick

10.18553/jmcp.2021.27.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 12, 2021 - April 16, 2021


Weight Gain After Switching Different Integrase Strand Transfer Inhibitors (INSTI)

Grace A. McComsey, MD, Paul E. Sax, Keri N. Althoff, Janna Radtchenko, Helena Diaz-Cuervo, Joshua Gruber, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion

vCROI 2021 Abstract eBook: Page 190-#503

Oral Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)

Conference dates: March 06, 2021 - March 10, 2021


A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice

Shawn X. Sun, Andrew Frick

DOI: 10.1111/hae.14236: ABS039

Poster Presented at: European Association for Haemophilia and Allied Disorders

Conference dates: February 03, 2021 - February 05, 2021




2020


Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic HCV Infection and Mental Health Disorders: Real-World Care Management from 8 Countries

Milligan S, Barrett L, Teti E, Garcia-Retortillo M, Wedemeyer H, Fraser C, Morano L, Rodriguez-Tajes S, Acosta-Lopez S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernandez-Rodriguez CM, Martins Figueiredo L, Fenech M, Jimenez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Ledinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernandez-Lopez C, and Di Marco V

DOI: 10.1002/hep.31579: 905

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2020

Conference dates: November 13, 2020 - November 16, 2020


Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)

Grace A. McComsey, Paul E. Sax, Keri N. Althoff, Todd T. Brown, Janna Radtchenko, Helena Diaz-Cuervo, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion

ID Week Virtual; 2020 October 21-25: LB-7

Oral Presented at: ID Week

Conference dates: October 21, 2020 - October 25, 2020


Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH)

M Keith Rawlings, MD Additional Authors: Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Moti Ramgopal, MD, Alan Oglesby, MPH, Faith Fletcher, PhD, and Richard A Elion, MD

ID Week Virtual; 2020 October 21-25: 1704

Poster Presented at: ID Week

Conference dates: October 21, 2020 - October 25, 2020


Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US

Simon Helfgott, Janna Radtchenko, Nehad Soloman, Kent Kwas Huston, Jasvinder Singh, and Colin Edgerton

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network

Simon Helfgott, Jeremy Broestl, Kent Kwas Huston, Deepali Rane, Jasvinder Singh, Nehad Soloman, and Colin Edgerton

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)

Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)

Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)

Colin Edgerton, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Jasvinder Singh, and Nehad Soloman

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases

Kent Kwas Huston, Simon Helfgott, Scott Milligan, Jasvinder Singh, Nehad Soloman, Brandon Weil, and Colin Edgerton

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak

Kent Kwas Huston, Nehad Soloman, Janna Radtchenko, Simon Helfgott, Jasvinder Singh, and Colin Edgerton

Arthritis Rheumatol. 2020; 72 (suppl 10)

Poster Presented at: ACR Convergence 2020

Conference dates: November 05, 2020 - November 09, 2020


Impact of Adherence on Viral Suppression with Bictegravir and Dolutegravir (DTG)- Containing Triple Therapy in Clinical Practice

Paul E. Sax, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Karam Mounzer, Moti Ramgopal, Steven Santiago, and Richard A. Elion

DOI: 10.1002/jia.2.25616: P029

Poster Presented at: HIV Glasgow

Conference dates: October 05, 2020 - October 08, 2020


Association of FIB-4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU037

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU036

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #FRI107

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Dr. Michael P Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU435

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C

Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT387

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Longer-Term Experience with Tenofovir Alafenamimde (TAF) in HBV-Infected Patients : Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression

K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT457

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT448

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020


Global Real-World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective HCV Treatment: Analysis of 5552 Patients From 12 Cohorts

Alessandra Mangia, Scott Milligan, Mandana Khalili, Stefano Fagiuoli, Stephen D. Shafran, Fabrice Carrat, Denis Ouzan, George Papatheodoridis, Alnoor Ramji, Sergio M. Borgia, Heiner Wedemeyer, Ruggero Losappio, Francisco Perez-Hernandez, Nicole Wick, Robert S. Brown Jr., Pietro Lampertico, Karen Doucette, Ioanna Ntalla, Heribert Ramroth, Michael Mertens, Kim Vanstraelen, and Juan Turnes

DOI: 10.1111/liv.14537

Manuscript Published in: Liver International

Date of Publication: May 25, 2020


Evaluation of Liver Outcomes Relative to Use of GLP-1 Receptor Agonists (GLP1A) and/or SGLT-2 Inhibitors (SGLT2I) in Real-World Populations Diagnosed With Type II Diabetes (T2DM) and NASH/NAFLD or At Risk of NASH

Michelle Lai, Jeremy Broestl, Andrew Frick, Kavita Juneja, Scott Milligan, Zobair Younossi, and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020


Lean and Obese Patients With Non-Alcoholic Steatohepatitis (NASH) / Non-Alcoholic Fatty Liver Disease (NALFD); Comparisons of Populations and Disease Progression

Michelle Lai, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020


Hepatitis B Treatment Patterns in US Clinical Care Following TAF Approval

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Kimmi Cox, and Nezam Afdhal

DOI: 10.1016/j.jval.2020.04.484

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020


Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions

Keith Rawlings, MD, Paul Sax, MD, Julie Priest MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Joe Eron, MD, Alan Oglesby, MPH, Keri Althoff, PhD, Faith Fletcher, PhD, Moti Ramgopal, MD, Steven Santiago, MD, Richard A Elion, MD

23rd International AIDS Conference Virtual; 2020 July 6-10: PEB0354

Poster Presented at: International AIDS Conference (IAS)

Conference dates: July 06, 2020 - July 10, 2020


Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens

Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, and Richard A. Elion

DOI: 10.1016/j.jval.2020.04.480

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020


Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens

Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, and Richard A. Elion

The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2020 Mar 8-11: 495

Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)

Conference dates: March 08, 2020 - March 11, 2020


DO PRESCRIBING DATA REFLECT ACTUAL TREATMENT IN PEOPLE WITH HIV?

Joseph J. Eron, Dushyantha Jayaweera, Gregory D. Huhn, Kelsey Milligan, Scott Milligan, Paul E. Sax, Keith Spitz, and Richard A. Elion

The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2020 Mar 8-11: 499

Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)

Conference dates: March 08, 2020 - March 11, 2020


Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI)

Grace A. McComsey, Keri N. Althoff, Todd T. Brown, Joseph J. Eron, Gregory D. Huhn, Anthony Mills, Graeme Moyle, Soodi Navadeh, Janna Radtchenko, Paul E. Sax, and Richard A. Elion

The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2020 Mar 8-11: 676

Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)

Conference dates: March 08, 2020 - March 11, 2020


Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV

Sonia Vibhakar Patel, Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn

DOI: 10.1371/journal.pone.0228847

Manuscript Published in: PLOS ONE

Date of Publication: February 13, 2020


Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States

Shawn X. Sun, Scott Milligan

Res Pract Thromb Haemost. 2020; 4 (Suppl 1)

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 12, 2020 - July 14, 2020


A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH

DOI: 10.18553/jmcp.2020.26.4.492

Manuscript Published in: Journal of Managed Care & Specialty Pharmacy

Date of Publication: April 01, 2020


Outpatient Costs in Rheumatoid Arthritis (RA) Patients With VS Without Comorbidities

Colin Edgerton, Janna Radtchenko, and V. Michael Holers

DOI: 10.1016/j.jval.2020.04.691

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 22, 2020


Real-World Effectiveness of Hepatitis C Virus (HCV) Treatment With Direct-Acting Antivirals (DAA) In Populations With Fatty Liver/Non-Alcoholic Steatohepatitis (FL/NASH), Decompensated Cirrhosis (DCC), Hepatocellular Carcinoma (HCC), and/or Post Liver Transplant (PTX)

Zobair Younossi, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020


Real-World Effectiveness Of Direct-Acting Antivirals (DAA) In Young Adult (18-25) and Elderly (80+) Populations With Hepatitis C (HCV)

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020


Association of FIB-4 score with Major Cardiovascular Events (MACE) in real-world populations diagnosed with NASH or NAFLD in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: May 02, 2020 - May 05, 2020


Association of FIB4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 02, 2020 - May 05, 2020


Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 02, 2020 - May 05, 2020


Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naıve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Steven L. Flamm, Jens Kort, Steven E. Marx, John Strezewski, Douglas E. Dylla, Bruce Bacon, Michael P. Curry, Naoky Tsai, and Nicole Wick

Manuscript Published in: Advances in Therapy

Date of Publication: April 11, 2020


Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV

Sonia Vibhakar Patel, Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Janna RadtchenkoI, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn

DOI: 10.1371/journal.pone.0228847

Manuscript Published in: PLOS ONE

Date of Publication: February 13, 2020


Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic HCV Infection: A Meta-Analysis

Pietro Lampertico, Jose A. Carrion, Michael Curry, Juan Turnes, Markus Cornberg, Francesco Negro, Ashley Brown, Marcello Persico, Nicole Wick, Ariel Porcalla, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Hu, and Heiner Wedemeyer

Manuscript Published in: Journal Of Hepatology

Date of Publication: February 12, 2020




2019


Real-world effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naive, noncirrhotic patients with HCV infection in the TRIO network

Michael P. Curry, Jens Kort, Steve Marx, John Strezewski, Nicole Wick, Steven L. Flamm, Bruce Bacon, and Naoky Tsai

Manuscript Published in: GastroHep Wiley

Date of Publication: November 23, 2019


Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Dr. Michael P. Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019

Conference dates: November 08, 2019 - November 12, 2019


Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C” – Poster of Distinction Award

Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P. Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019

Conference dates: November 08, 2019 - November 12, 2019


Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies

R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera

The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19

Poster Presented at: European AIDS Clinical Society (EACS)

Conference dates: November 06, 2019 - November 09, 2019


Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis

Markus Cornberg, Francesco Negro, Pietro Lampertico, Juan Turnes, Michael P Curry, Ashley Brown, Heiner Wedemeyer, Jose A. Carrion, Nicole Wick, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, and Marcello Persico

Poster Presented at: American College of Gastroenterology

Conference dates: October 25, 2019 - October 30, 2019


Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

Naoky Tsai, MD, Bruce Bacon, MD, Michael Curry, MD, Steven L. Flamm, MD, Scott Milligan, PhD, Nicole Wick, AS, Zobair Younossi, MD, and Nexam Afhdal, MD

Manuscript Published in: American Journal of Managed Care (AJMC)

Date of Publication: July 12, 2019


Global Real World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective Regimen for the Treatment of Chronic Hepatitis C: Integrated Analysis of 12 Clinical Practice Cohorts

Dr. Alnoor Ramji, Dr. Alessandra Mangia, Dr. Scott Milligan, Prof. Mandana Khalili, Prof. Stefano Fagiuoli, Dr. Stephen D. Shafran, Prof. Fabrice Carrat, Prof. Denis Ouzan, Prof. George Papatheodoridis, Dr. Sergio M. Borgia, Prof. Heiner Wedemeyer, Valeria Piazzolla, Francisco Perez, Ms. Nicole Wick, Dr. Dawn Fishbein, Prof. Pietro Lampertico, Dr. Karen Doucette, Dr. Michael Mertens, Dr. Kim Vanstraelen, Dr. A. Anna Cumaraswamy, and Dr. Juan Turnes

Oral Presented at: Canadian Liver Meeting

Conference dates: May 24, 2019 - May 26, 2019


Access to HCV Cure Under Medicaid Programs in the United States

Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: April 10, 2019 - April 14, 2019


Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion

The 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2019; 70 (suppl 1): Abstract #486

Poster Presented at: American Association for the Study of Liver Disease (AASLD)

Conference dates: November 08, 2019 - November 12, 2019


Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression

K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2019; 70 (suppl 1): Abstract #487

Poster Presented at: American Association for the Study of Liver Disease (AASLD)

Conference dates: November 08, 2019 - November 12, 2019


Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal

DOI: 10.1016/j.jval.2019.04.883

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal

DOI: 10.1016/S0618-8278(19)30912-0

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies

R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera

The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19

Poster Presented at: European AIDS Clinical Society (EACS)

Conference dates: November 06, 2019 - November 09, 2019


Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion

The 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV

Grace A McComsey, Joseph J Eron, Steven Santiago, Karam Mounzer, Graeme Moyle, Thanes Vanig, Paul E Sax, Keri N Althoff, Scott Milligan, Richard, Haubrich, and Richard A Elion

The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2019 Mar 4-7: 671

Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)

Conference dates: March 04, 2019 - March 07, 2019


Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, and Edward Drea

DOI: 10.1182/blood-2019-124319

Abstract Presented at: The American Society of Hematology (ASH)

Conference dates: December 07, 2019 - December 10, 2019


Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

Colin C. Edgerton, Janna Radtchenko, and V. Michael Holers

Arthritis Rheumatol. 2019; 71 (suppl 10): Abstract #1138

Poster Presented at: 2019 ACR/ARP Annual Meeting

Conference dates: November 08, 2019 - November 13, 2019


Misdiagnosis of Desmoid Tumors; Insight From the Desmoid Tumor Research Foundation (DTRF) Patient Registry

Kelly Mercier, Lynn Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, and Kelsey Milligan

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 21, 2019 - October 22, 2019


Quality of Life in Pediatric Patients With SYNGAP1-Related Non-Syndromic Intellectual Disability (NSID); Data From the SYNGAP1 (MRD5) Patient Registry

Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, and Milligan K

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 21, 2019 - October 22, 2019


The PKU Patient Registry: Understanding The Natural History of PKU

Olaf Bodamer, Harvey Levy, Eileen Blakely, Christine Brown, Hilary Feldman, Rhonda Connolly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Kelsey Milligan, Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 21, 2019 - October 22, 2019


Quality of Life and Demographics of Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Caroline Kruse, Alexandra Kruse, Nancy Potthast, Vanessa Boulanger, Allison Seebald, Suzanne Rossov and Kelsey Milligan

DOI: 10.1097/01.HS9.0000567492.92876.8b

Poster Presented at: European Hematology Association (EHA)

Conference dates: June 13, 2019 - June 16, 2019


Quality of Life (QOL) and Tumor Location in Patients With Desmoid Tumors; Data From The Desmoid Tumor Research Foundation (DTRF) Natural History Study

Kelly Mercier, Lynne Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Kelsey Milligan

DOI: 10.1200/JCO.2019.37.15_suppl.e18291 Journal of Clinical Oncology 37, no. 15_suppl

Poster Presented at: ASCO

Conference dates: May 31, 2019 - June 04, 2019


Understanding Disease and Burden in Syngap1-Related Non-Syndromic Intellectual Disability (NSID) Using a Patient Registry Database

Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J.

DOI: 10.1016/j.jval.2019.04.1689

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


Understanding Real-World Treatment Patterns and Quality of Life in Patients with Pemphigus and Pemphigoid Using a Patient Registry Database

Yale ML, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J

DOI: 10.1016/j.jval.2019.04.1697

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


The Use of a Patient Registry to Better Inform Healthcare Decision Makers and Improve Clinical Outcomes for Patients with Phenylketonuria (PKU)

Bodamer O, Levy H, Blakely E, Brown C, Feldman H, Connolly R, and Moseley K, Boulanger V, Seebald A, Rossov S, Milligan K, Radtchenko J

DOI: 10.1016/j.jval.2019.04.1701

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


The Use of Patient Reported Registry Data to Improve Health Outcomes for Patients with Opsoclonus Myoclonus Syndrome (OMS)

Michaelis M, Khoury-Dennis C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J

DOI: 10.1016/j.jval.2019.04.1698

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


Understanding Demographics and Diagnosis in Syngap1-related Non-Syndromic Intellectual Disability (NSID) Patients Using a Patient Registry Database

Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov K, and Milligan K

The Power of Patients: Informing Our Understanding of Rare Diseases: Posters and Acknowledgements

Poster Presented at: National Institute of Health (NIH)

Conference dates: February 28, 2019 - February 28, 2019


Effectiveness and Safety with Tenefovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal

DOI: 10.1007/s12072-019-09936-5: Abstract#627

Oral Presented at: Asian Pacific Association for the Study of the Liver (APASL)

Conference dates: February 20, 2019 - February 24, 2019


Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

Maureen Watt and Scott Milligan

DOI: 10.1182/blood-2019-124101

Manuscript Published in: The American Society of Hematology (ASH)

Date of Publication: December 07, 2019


A Retrospective, Observational Study Using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States

Maureen Watt and Scott Milligan

DOI: 10.1002/rth2.12229

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 06, 2019 - July 10, 2019


Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network

Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019




2018


Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network

Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOF-VEL): Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network

Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai, and Nezam Afdhal

Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


The Impact of Individual Patient Data in a Network Meta-Analysis: An Investigation into Parameter Estimation and Model Selection

Joy Leahy, Aisling O'Leary, NEzam Afdhal, Emma Gray, Scott Milligan, Malte H. Wehmeyer, and Cathal Walsh

Manuscript Published in: Research Synthesis Methods

Date of Publication: June 20, 2018


Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Global Hepatitis Summit (GHS)

Conference dates: June 14, 2018 - June 17, 2018


Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0016-5085(18)33931-3

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer

DOI: 10.1016/S0016-5085(18)33670-9

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses from the TRIO Network

S.L. Flamm, B. Bacon, M. P. Curry, S. Milligan, C. U. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal

Manuscript Published in: Alimentary Pharmacology & Therapeutics (AP&T)

Date of Publication: April 17, 2018


Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0168-8278(18)30723-2

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0168-8278(18)30735-9

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Clinical Observations of Antiretroviral (ART) Switching in HIV-Suppresed Patients After Availability of TAF

Richard Elion, Joseph Eron, Steven Santiago, Paul Sax, Moti Ramgopal, Greg Huhn, Scott Milligan, Keri Althoff, and Jonathan Winston

DOI: 10.1002/jia.2.25187: P114

Poster Presented at: HIV Glasgow

Conference dates: October 28, 2018 - October 31, 2018


Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer

DOI: 10.1016/S0016-5085(18)33670-9

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0016-5085(18)33931-3

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0168-8278(18)30723-2

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0168-8278(18)30735-9

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 02, 2018 - June 05, 2018


Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States

Shawn X. Sun, Scott Milligan

Res Pract Thromb Haemost. 2020; 4 (Suppl 1)

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 12, 2020 - July 14, 2020


A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH

DOI: 10.18553/jmcp.2020.26.4.492

Manuscript Published in: Journal of Managed Care & Specialty Pharmacy

Date of Publication: April 01, 2020


The Opsoclonus Myoclonus Syndrome (OMS) Registry: A Vehicle to Better Understand the Natural History and Experience of OMS Patients

Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


Symptoms and Diagnosis of Opsoclonus Myoclonus Syndrome (OMS): Early Data from the OMS Registry

Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


Treatment Utilization by Patients with Opsoclonus Myoclonus Syndrome (OMS): Insights from the OMS Registry

Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


NORD RareCare® Assistance Programs: Helping the Rare Disease Community Access Diagnostics and Care

Jill Pollander, Pamela Gavin, and Jeremy Broestl

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


The Pemphigus-Pemphigoid Registry: Real-World Diagnostic and Treatment Patterns

Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


The Pemphigus-Pemphigoid Registry: First Report of Patient Quality of Life Measures

Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


The Pemphigus-Pemphigoid Registry: A Platform to Improve Understanding and Advance Care

Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


The PKU Patient Registry: A Step for Better Disease Awareness and Improved Patient Outcomes

Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


The PKU Patient Registry: Understanding Diagnosis and Medical History of Patients with PKU

Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


The PKU Patient Registry: Evaluating Treatment Paradigms of Patients with PKU

Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster Presented at: National Organization for Rare Disorders (NORD)

Conference dates: October 15, 2018 - October 16, 2018


Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network

Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal

DOI: 10.1111/apt.14635

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2018; 68 (suppl 1): Abstract #423

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018




2017


Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network

M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network

Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network

C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)

C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 06, 2017 - May 09, 2017


Sofosbuvir/Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV

Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: May 06, 2017 - May 09, 2017


Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 06, 2017 - May 09, 2017


Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 06, 2017 - May 09, 2017


Sofosbuvir/Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV

Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Real-World Treatment Utilization and Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from The TRIO Network

S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network

Z. Younossi, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, and N. Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017




2016


Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Kris V. Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 11, 2016 - November 15, 2016


Real-World Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: the Trio Health Study

E. B. Tapper, B. R. Bacon, M. P. Curry, D. T. Dieterich, S. L. Flamm, L. E. Guest, K. V. Kowdley, Y. Lee, N. C. Tsai, Z. M. Younossi, and N. H. Afdhal

Manuscript Published in: Journal of Viral Hepatitis

Date of Publication: October 11, 2016


Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes With Ledipasvir and Sofosbuvir in a Real-World Cohort Study

Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry, Douglas T. Dieterich, Steven L. Flamm, Lauren E. Guest, Kris V. Kowdley, Yoori Lee, Naoky C. Tsai, Zobair M. Younossi, and Nezam H. Afdhal

Manuscript Published in: Hepatology

Date of Publication: August 17, 2016


Effectiveness of 8 or 12 week LDV/SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 21, 2016 - May 25, 2016


Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 21, 2016 - May 25, 2016


Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016


Access to Therapy in Era of DAA Regimens: Real-World Experience from the TRIO Network

Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016


Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016


Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: International Liver Transplantation Society (ILTS)

Conference dates: May 04, 2016 - May 07, 2016


Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2016 - April 17, 2016


Ledipasvir/Sofosbuvir+/-Ribavirin in HCV Post-Transplant Patients: Real-world Heterogeneous Population from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2016 - April 17, 2016


No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients in the TRIO Network

Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2016 - April 17, 2016


Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: Asian Pacific Association for the Study of the Liver (APASL)

Conference dates: February 20, 2016 - February 24, 2016


Disparate Access to Treatment Regimens in Chronic Hepatitis C Patients: Data from The TRIO Network

Z. M. Younossi, B. R. Bacon, D. T. Dieterich, S. L. Flamm, K. Kowdley, S. Milligan, N. Tsai, and A. Nezam

Manuscript Published in: Journal of Viral Hepatitis

Date of Publication: February 03, 2016




2015


Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 13, 2015 - November 17, 2015


Effectiveness of 12 or 24 Week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 13, 2015 - November 17, 2015


Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Nezam Afdhal, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 13, 2015 - November 17, 2015


Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015


Evaluation of Access to Care in Patients Prescribed Sofosbuvir-Containing Regimens; Data from the TRIO Network

Zobair Younossi, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, and Naoky Tsai

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015


Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Douglas Dieterich, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015


Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients Over 70 Years; Data from the TRIO Network

Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015


Final Evaluation of HCV Patients Treated With 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Soctt Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 22, 2015 - April 26, 2015


Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network

Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 22, 2015 - April 26, 2015


Efficacy Evaluation of 24-Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 22, 2015 - April 26, 2015




2014


Evaluation of Sofosbuvir and Olysio-Based Regimens in the Trio Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

D Dieterich, B Bacon, S Flamm, K Kowdley, S Milligan, N Tsai, Z Younossi, and E Lawitz

Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 07, 2014 - November 11, 2014


Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network

Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Naoky Tsai

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 07, 2014 - November 11, 2014


Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network

Steven Flamm, Bruce Bacon, Douglas Dieterich, Kris Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 07, 2014 - November 11, 2014